Recruiting
Phase 4

Ibuprofen with Cyclobenzaprine

Sponsor:

Christiana Care Health Services

Code:

NCT07664956

Conditions

Minimally Invasive Surgical Procedures

Abnormal Uterine Bleeding, Unspecified

Adenomyosis of Uterus

Fibroid Uterus

Chronic Pelvic Pain

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cyclobenzaprine

Study Details

Brief summary:

Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.

Conditions

Minimally Invasive Surgical Procedures

Abnormal Uterine Bleeding, Unspecified

Adenomyosis of Uterus

Fibroid Uterus

Chronic Pelvic Pain

Study ID

NCT07664956

Start date

Sep 1, 2026

Status verified date

Nov, 2026

Completion date

May 1, 2027

Anticipated

Primary completion date

May 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age >18yo
  • Female
  • English speaking
  • Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy
  • If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included
  • Surgery took place at ChristianaCare Hospitals
  • No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine

Exclusion Criteria:

  • Age <18yo
  • Male
  • Pregnant, breastfeeding
  • Non-English speaking
  • Primary procedures other than laparoscopic hysterectomy
  • Laparoscopic myomectomy
  • Laparoscopic resection of endometriosis
  • Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy
  • Hysteroscopic procedures
  • Bartholin gland marsupialization
  • Operations that are scheduled as or converted to the open approach
  • Procedures with planned or unplanned bladder or bowel surgery
  • Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage/failure, bariatric surgery, history of gastric ulcer, etc.
  • Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management
  • Currently undergoing medication assisted treatment for opioid use disorder
  • Currently using opioids consistently
  • Allergies or contraindications to cyclobenzaprine:
  • Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome
  • Allergies or contraindications to inactive ingredients in Flexeril, such as lactose
  • Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates

Study Design

Enrollment

36 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

no intervention: Control

No additional intervention

experimental: Cyclobenzaprine

5mg cyclobenzaprine q8h for one week postoperatively

Interventions

Cyclobenzaprine

5mg cyclobenzaprine q8hr for one week postoperatively after minimally invasive hysterectomy

Primary outcome measure

  • Visual Analog Scale (VAS) Pain Score on Post Op Day 3 [ Time Frame: 3 days postoperatively ]

Central Contacts and Locations

Central contacts

Locations

ChristianaCare Health System

Recruiting

Newark, Delaware, United States, 19718

More Information

Sponsor

Christiana Care Health Services

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Keywords

  • cyclobenzaprine
  • flexeril
  • hysterectomy
  • minimally invasive hysterectomy
  • pain control
  • multimodal pain control

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Christiana Care Health Services on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.